The proposed rule would allow plans to make broader use of prior authorization and step therapy for drugs—including drugs in protected classes—that are covered under Part D.
As part of the Trump administration’s blueprint to lower drug prices and reduce out-of-pocket spending for patients, CMS this week issued a proposed rule aimed at reducing the cost of Part D drugs.
Under the proposed rule, Part D sponsors would be allowed to exclude drugs from formulary if they represent only new formulations of existing single-source drugs or biologics, and they also are allowed to exclude drugs if their prices exceed a certain threshold over a specified look-back period. These provisions, says CMS, will allow plans to negotiate better prices for drugs, and could save the government $1.85 billion—and save enrollees $692 million in cost-sharing—by 2029.
Furthermore, the rule allows plans to make broader use of prior authorization and step therapy for drugs—including drugs in protected classes—that are covered under Part D.
CMS has already allowed step therapy for Part B drugs, which are physician-administered therapies (including biologics such as infliximab, rituximab, and other infused products). The newly announced proposed rule would create a similar policy for self-administered Part D drugs (including biologics such as pegfilgrastim, etanercept, and adalimumab).
Under the proposal, only new patients would be subject to step therapy for their Part D therapies, and step therapy requirements would have to be reviewed and approved by a plan’s pharmacy and therapeutics committee. Additional requirements stipulate that plans must continue to cover at least 2 drugs per class.
According to a CMS blog post authored by HHS Secretary Alex Azar and CMS Administrator Seema Verma, step therapy for Part D drugs could include a beneficiary starting treatment with a low-cost biosimilar before receiving a costlier biologic.
“Some say that allowing step therapy and prior authorization would restrict access to prescription drugs. However, these changes protect patient access, as the Part D program is embedded with strong patient protections,” wrote Azar and Verma. “CMS reviews plan formularies to guard against discriminatory practices, and the agency has in place an expedited appeals process for cases in which a physician recommends an exception to prior authorization or other forms of management.”
Provider groups were quick to respond to CMS’ proposal; the Community Oncology Alliance (COA) issued a statement saying that the push to use step therapy is driven by financial interests, not by the best interests of those receiving medical treatment.
“Patients are left at the whim of insurance and pharmacy benefit manager middlemen who are more concerned with their profit margins than patient outcomes, side effects, and wellbeing,” COA’s president, Jeff Vacirca, MD, FACP, said in a statement. “Treatment decisions are made by nameless and faceless corporate bureaucrats who are often not board certified in the diseases they are making coverage decisions over,” he added.
Other provisions of the proposal include requiring explanations of benefits to include drug pricing information, requiring plans to adopt real-time benefit management tools that can inform prescribers when lower-cost therapies are available, prohibiting so-called gag clauses in pharmacy contracts, and redefining baseline payments to pharmacies as a means to reduce cost-sharing and out-of-pocket costs for beneficiaries.
CMS will accept comments on the proposed rule until January 25, 2019.
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 1st 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Biorationality: Advice for the FDA, Biosimilar Developers on Reducing the Cost of Clinical Testing
May 15th 2023Although the FDA has consistently edited its testing guidelines for biosimilar developers over the years, clinical testing is still very expensive and time-consuming. Sarfaraz K. Niazi, PhD, offers the FDA and companies a plan of action for reducing clinical testing expenses for biosimilar products.
Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
May 11th 2023The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.
2 Clarke Drive
Cranbury, NJ 08512